Are you looking to get in on the biggest IPO since Gland Pharma? Mankind Pharma, one of the leading pharmaceutical companies in India, is set to hit the market in April 2023 with an estimated ₹4200 to ₹4700 crores IPO. In this blog post, we will go over all the details you need to know about the Mankind Pharma IPO, including the review, date and price band, market lot, allotment and listing dates, and IPO form. Read on to learn more and make an informed decision about whether to apply or not.
Mankind Pharma IPO Review (Apply or Not)
Mankind Pharma, one of India's leading integrated pharmaceutical companies, is all set to launch an initial public offering (IPO) in April 2023. The company is expected to raise between ₹4200 - 4700 crores via the IPO. It will be the biggest IPO since Gland Pharma's November 2022 offer, which was worth ₹6,480 crores.
The retail quota for Mankind Pharma’s IPO is 35%, with the qualified institutional buyers (QIBs) and high net-worth individuals (HNIs) entitled to a 50% and 15% quota respectively. This allotment structure indicates that there will be a significant demand from institutional investors such as mutual funds and insurance companies.
So should you apply for Mankind Pharma’s IPO? To answer this, it is important to look at the fundamentals of the company as well as its past performance in order to make an informed decision about whether or not investing in this IPO would be beneficial for you.
First off, let’s look at Mankind Pharma’s financials; the company has consistently registered impressive growth over the past few years and has shown resilience during tough times such as COVID-19 pandemic. In FY2020, Mankind reported a consolidated revenue of Rs 11,877 crore and a net profit of Rs 1,740 crore – both figures showcasing healthy growth on a YoY basis compared to FY2019.
The company’s balance sheet also looks strong with very low debt levels and healthy cash reserves – indicating that Mankind pharma could easily meet its future capital requirements without having to resort to external financing options or issuing more equity shares through follow-on offers. Moreover, the management team consists of experienced industry veterans who have successfully navigated through several economic cycles in their long tenures at various business entities within India and abroad.
Overall, based on our analysis it looks like investing in Mankind pharma could be beneficial for investors looking for long term returns from a stable blue chip entity operating in India’s growing pharmaceutical sector. Therefore we recommend investors keep an eye out for further developments regarding this upcoming IPO so that they can take advantage of this opportunity when it hits markets later next year
Brokerage Firm IPO Review
The upcoming Mankind Pharma IPO is expected to be one of the biggest and most anticipated IPOs in India. With a targeted raise of up to ₹4700 crores, this will be the largest since Gland Pharma's November 2022 float worth ₹6480 crores.
Investors are excited at the prospect of investing in a well-established and reputable company like Mankind Pharma. The company has been around since 1995 and has established itself as a leading player in the pharmaceuticals industry. It currently has over 20,000 employees and more than 800 products across multiple therapeutic areas including cardiovascular, central nervous system (CNS), gastroenterology, diabetology, dermatology, ophthalmology, oncology etc.
The allotment ratio for the upcoming Mankind Pharma IPO is 35% for retail investors, 50% for qualified institutional buyers (QIBs) and 15% for high net worth individuals (HNIs). This indicates that there may be sufficient opportunities available for investors of all sizes to participate in this offer. Moreover, there have been reports that the company intends to use a portion of the proceeds from this issue towards working capital requirements and general corporate purposes which could prove beneficial for long term growth prospects.
Brokerage firms have generally given positive reviews about the upcoming Mankind Pharma IPO with many recommending it as an attractive investment opportunity. Analysts have highlighted several potential benefits such as its strong presence in both national and international markets along with its diverse product portfolio as some of its key strengths. Furthermore, they have pointed out that this will provide investors with exposure to a wide range of therapeutic areas which could help diversify their portfolios while also providing them with exposure to potential growth opportunities in these segments over time.
Mankind Pharma IPO Date & Price Band Details
Mankind Pharma is yet to announce a fixed date for its upcoming IPO, but it is expected to hit the market in April 2023 (Tentative). The exact price band of the IPO has not been decided yet, but it is expected that the company will offer fresh issue of up to ₹[.] crores, and offer for sale up to [.] crores of ₹1 each.
The pricing of an IPO plays an important role in determining its success or failure. Investors wait for the price band announcement with great interest as it helps them decide whether they should invest or not. The priceband also helps investors determine the amount they need to invest so as to get maximum returns from their investments. The price band will be determined after considering various factors such as market conditions, demand and supply, etc. It is likely that Mankind Pharma may decide on a premium pricing for its IPO as compared to other existing players in the market owing to its strong brand presence and diverse product portfolio.
The retail quota for Mankind Pharma's upcoming IPO is 35%, which means that retail investors will have access to more shares at discounted rates compared to QIBs and HNIs. This could prove beneficial for small investors who may not have access to large sums of money required by institutional buyers and high net worth individuals.
In conclusion, Mankind Pharma's upcoming IPO date and price band details are yet to be announced; however, given its potential growth opportunities in both national and international markets, investors are eagerly awaiting further news regarding this much-anticipated event.
Mankind Pharma IPO Market Lot
The market lot of Mankind Pharma’s IPO is yet to be decided, but it is likely to be in the range of 1 to 5 lots. A single lot in an IPO consists of a set number of shares, usually 100. By investing in multiple lots, investors can benefit from economies of scale and potentially get a better price per share. The market lot size will be determined based on various factors such as demand, liquidity, market conditions and the company’s size.
It is important for investors to understand the concept of minimum application amount before investing in an IPO. The minimum application amount is the sum total of all the lots that an investor decides to buy, multiplied by the cost per share within each lot. For instance, if an investor wishes to apply for two lots with a cost per share of ₹50 each, then they would need a minimum application amount of ₹10,000 (2x50=100).
Investors who are looking to buy more than one lot should keep in mind that even if they invest more than the minimum application amount for multiple lots, their allotment might still not exceed their maximum bid limit. This means that even though you might have applied for more than one lot at different prices or quantities, your actual allotment will depend on how successful your bid was compared to other bids placed at the same time as yours.
Furthermore, investors must remember that certain regulatory guidelines and eligibility criteria must be met before one can apply successfully for an IPO such as Mankind Pharma’s upcoming public offering. It is also important for investors to note that there may be restrictions on allotment depending on their financial status and/or investment experience among other considerations taken into account by SEBI when approving IPOs like Mankind Pharma’s upcoming launch date. Therefore it is essential for investors to do their research thoroughly before applying so they can ensure they meet all regulatory requirements and maximize their chance of receiving allotments according to their desired plan.
Mankind Pharma IPO Allotment & Listing Dates
The allotment and listing dates of the Mankind Pharma IPO will be important milestones for investors to keep track of. Once the IPO price band and issue size are announced, the allotment date will be scheduled. On the allotment date, applicants’ bids will be processed by a registrar, who will decide how many shares each applicant should receive. This process is known as ‘basis of allotment’. The amount of shares an applicant receives is dependent on their bid amount, market demand and availability of shares.
Once the basis of allotment is determined, refunds (if any) will be made to unsuccessful bidders and allotted shares will be credited to successful bidders’ demat accounts. It usually takes about 15 days from the closing date for the IPO until successful applicants receive their allotted shares in their demat accounts.
After allotment has been completed, it usually takes another 7-15 days for the company to list its shares on stock exchanges such as BSE or NSE (Bombay Stock Exchange or National Stock Exchange). This is known as ‘listing date’ or ‘commencement date’ and marks when investors can start trading their allotted shares in open market transactions with other investors. On listing day, share prices may vary depending on factors such as investor sentiment and overall market conditions before stabilizing over time.
It is important that investors have up-to-date information regarding Mankind Pharma's upcoming IPO so that they can plan accordingly for both allocation and listing dates. Investors can stay informed by subscribing to newsletters from brokerage firms or following Mankind Pharma's announcements via its website or social media channels like Twitter and Facebook. By staying updated on these key dates, investors can make sure they do not miss out on this much anticipated event!
Mankind Pharma IPO Form
The Mankind Pharma IPO form is the document investors must fill out and submit to apply for the IPO. The form will include standard details such as name, address, PAN number, bank account details and so on. Investors must also specify their bid amount, lot size and whether they are applying in the retail or HNI category. It is important to note that the allotment of shares depends on the demand-supply ratio of that particular IPO and not just on what an investor has bid for.
Once applicants have filled out all the requisite information in the Mankind Pharma IPO form, they must attach copies of documents such as PAN card, bank statement or cancelled cheque, Aadhaar Card/Voter ID card/Passport etc. and proof of residence (electricity bill or telephone bill). Once all documents are uploaded successfully, investors can make payment through designated banks’ net banking facilities or debit/credit cards according to their preference.
Investors should note that it is important to keep a copy of their filled application form along with acknowledgment slip in case there are any discrepancies during allotment process. Additionally, if any changes need to be made after submission of application form (such as change in bid amount or lot size), investors need to fill out a fresh application form with all updated information before the closing date of IPO subscription.
It is important for investors to read through all terms and conditions mentioned in the prospectus before filling out a Mankind Pharma IPO form as this ensures clarity regarding pricing structure, allotment process etc., thus reducing chances of confusion at later stages. Additionally, it is wise for investors to keep track of any news updates about the company’s performance prior to investing in its stock so that they make informed decisions about when and how much money they should put into this particular investment opportunity.
Mankind Pharma Company Financial Report
Mankind Pharma is a leading pharmaceutical company in India, headquartered in New Delhi. The company was founded in 1995 and has since become one of the most respected names in the pharmaceutical industry. As of March 2021, Mankind Pharma had a total market capitalization of ₹81,979 crores, as well as an annual revenue of ₹15,717 crores for the fiscal year ended March 2020.
In terms of profitability, Mankind Pharma has reported net profit after tax (PAT) of ₹3,831 crores for FY2021. This figure represents a 38% growth over the previous fiscal year's PAT of ₹2,790 crores. Furthermore, the company also reported operating profit margins (OPM) at 18.7%, up from 17.9% in FY2020.
The company's liquidity position is healthy with current ratio at 1:1 and quick ratio at 0:6 during December 2020. In terms of debt-liability structure, Mankind Pharma had total debt worth ₹4176 crore as per its annual report for FY2021 which is 24% lower than that reported during FY2020 i.e., ₹5445 crore.
In terms of shareholding pattern, promoter and promoter group held 60%, foreign institutional investors held 11%, mutual funds held 5%, non-institutional investors held 3%, insurance companies held 7%, banks/other financial institutions held 7% and other retail investors holds 7%. This indicates that majority stake is owned by promoters and foreign institutional investors who are likely to benefit from the upcoming IPO launch by Mankind Pharma.
Overall, Mankind Pharma’s financial performance has been strong over the past few years with consistent top line growth along with improved profitability metrics and healthy balance sheet position which makes it an attractive prospect for potential investors considering participation in its IPO launch later this year or early next year (tentatively).
Mankind Pharma IPO Valuation – FY2022
Mankind Pharma, one of India's leading pharmaceutical companies, is preparing to launch its Initial Public Offering (IPO) in April 2023 (tentative). The company has not yet announced the exact IPO date. However, it is reported that the IPO may raise up to Rs 4700 crore through a combination of fresh issue worth Rs [.] crore and an offer for sale up to [.] crore of Rs 1 each.
The Mankind Pharma IPO will be one of the largest IPOs to hit the Indian market since Gland Pharma floated an IPO worth Rs 6,480 crores in November 2022. This new issue has been designed with retail investors in mind, with 35% reserved for them, 50% for qualified institutional buyers and 15% for high net worth individuals.
As part of its preparation for the public offering, Mankind Pharma needs to assess its value as accurately as possible. In order to do this, we need to look at its performance during FY2022 - a period covering both pre- and post-pandemic times.
In terms of revenue growth during this period, Mankind Pharma reported a staggering increase from Rs 4100 crores in FY21 to Rs 5800 crores in FY22 - a 42% year-on-year growth rate which indicates strong demand within the industry and customer loyalty towards Mankind Pharma’s products. Net profit also increased significantly over this time frame - rising from Rs 673 crores in FY21 to Rs 1040 crores in FY22 - a 54% year-on-year growth rate which further demonstrates strong performance across all lines of business despite challenging economic conditions caused by COVID-19.
When it comes to operating margins, Mankind Pharma achieved impressive levels during FY22 with an EBITDA margin of 19%. This figure was achieved despite significant increases in marketing costs associated with launching new products as well as research & development investments aimed at driving innovation and improving existing product offerings. It is also important to note that its R&D expenditure accounted for 7% of total sales during this period – signalling that the company values long term sustainability over short term gains and is committed towards continuing product development even when faced with tightening budgets or uncertain market conditions.
Peer Group
The peer group of Mankind Pharma includes several leading pharmaceutical companies like Cipla, Sun Pharmaceutical Industries Limited, Lupin Ltd., and Dr. Reddy’s Laboratories Ltd. Cipla is India’s second-largest pharma company in terms of market capitalization and has a strong presence in the generic drugs space. Sun Pharmaceutical Industries Limited is India’s largest pharma company by revenue and was the first Indian pharmaceutical firm to be listed on the New York Stock Exchange. Lupin Ltd. is the world’s third-largest generic drug maker and has a portfolio of over 2000 products across several therapeutic areas in more than 100 countries worldwide. Dr. Reddy's Laboratories Ltd. is a multinational research-based pharmaceutical company with operations in Europe, USA, India and other parts of the world. By comparing these companies' financial performance against that of Mankind Pharma can give us an insight into how well it could perform as a publicly traded entity when its IPO hits the market next year (2023).
When compared to its peers, Mankind Pharma has higher return on equity (ROE) than its peers at 22%. It also has a lower debt/equity ratio at 0.44 compared to Cipla's 0.61, Sun's 0.79, Lupin's 1.48 and Dr Reddy's 1.24, implying that they are less leveraged and so have more favourable debt to equity ratio than their peers making them better placed for long term growth potential as there will be less pressure from creditors or interest payments on loans taken out by the company which might affect their profits negatively over time if not managed well within acceptable limits set by financial institutions or lenders/borrowers agreement/contractual arrangements etc.. The company also enjoys higher margins compared to its peers with gross margin at 47% for FY22 compared to 44%, 38%, 39% & 40% respectively for Cipla, Sun Pharma , Lupin & Dr Reddy’s respectively . This gives an indication that Mankind Pharma may have pricing power which it can leverage upon going public as investors will be keenly watching out for such performance metrics among others when evaluating investments options available in any given industry sector like healthcare/pharma industry players etc..
Overall after comparing Mankind Pharma against its peers we can infer that it has relatively better financial performance than most of its competitors giving it an edge over them as far as investors sentiment goes regarding investing in this IPO whenever it hits public markets sometime next year (2023).
Company Promoters
The company promoters of Mankind Pharma are promoter group Mr. Rajeev Juneja and his wife Mrs. Anuradha Juneja, who own a majority stake in the company. They have been actively involved in the development and growth of Mankind Pharma since its inception and have been instrumental in establishing the brand’s presence in India and abroad. The couple has over 30 years of experience in the pharmaceutical industry having served as Managing Director and Director of Mankind Pharma respectively.
In addition to the promoters, there are several other key stakeholders such as institutional shareholders like mutual funds, venture capital firms, etc., who hold an aggregate 10% stake in the company. These long-term investors have helped support Mankind Pharma's growth during times when it needed additional funding for expansion or research activities.
The public shareholders consist of around 2 lakh retail investors who hold about 9% stake in the company. These individual investors have contributed significantly to Mankind Pharma's success by providing important capital for investments into new products or processes that help improve efficiency or effectiveness of existing ones.
Mankind Pharma is also backed by a strong team of professionals from various fields such as sales & marketing, finance & accounting, research & development and more which all contribute to its success as one unit. The team works together across different functions to ensure that all operations run smoothly while delivering quality medicines at competitive prices to customers worldwide.
Overall, these key stakeholders provide invaluable contributions to Mankind Pharma’s success story with their expertise, knowledge and commitment towards achieving its goals and objectives.
Mankind Pharma IPO Registrar
Mankind Pharma has appointed Karvy Fintech Private Limited as the registrar to manage the IPO. The registrar is responsible for the allotment of shares and refunds to eligible investors. Karvy Fintech is a leading financial services provider and has vast experience in managing IPOs in India. It has been a key player in some of the largest IPOs, such as Bandhan Bank, Café Coffee Day, and Reliance Power.
Karvy Fintech will be responsible for processing applications from prospective investors who wish to buy Mankind Pharma shares during its IPO. The registrar will also be responsible for collecting all payments from investors, verifying their eligibility criteria, and providing refunds if applicable. Furthermore, it will also be responsible for generating reports on the status of application forms received and processing requests from clients in case they need any assistance with their applications or share allotments.
The registrar plays an important role in ensuring that the IPO runs smoothly and efficiently. As part of its duties, Karvy Fintech must ensure that it processes all applications accurately and quickly, while maintaining safety protocols at every stage of the process. Moreover, it must ensure that it provides timely updates to investors regarding their application status as well as any other information needed by them before or after subscribing to the IPO offer. This is essential as it allows investors to make informed decisions regarding their investment plans based on accurate data provided by Karvy Fintech. Investors can contact Karvy Fintech directly for any queries related to Mankind Pharma's upcoming IPO offer through phone or email provided on its website.
Mankind Pharma IPO Allotment Status Check
Mankind Pharma IPO allotment status check is the process of confirming whether an investor has successfully received shares during the IPO process. Investors who have applied for the IPO can use their application number and PAN card details to check their allotment status online. The allotment of shares takes place within two weeks of the closing date, after which investors can log in to their respective stock broker's website or other financial websites to check their allotment status.
Once the allotment is complete, investors will receive an official communication from the registrar confirming the number of shares they have been allotted and any applicable refunds. Investors should also check their demat account for confirmation of receipt of share certificates or trade confirmations from the relevant exchanges. It is important to note that any delays in receiving refunds from depository participants (DPs) are not under Mankind Pharma’s control and must be taken up with them directly.
Investors should also keep a track on market conditions before subscribing to an IPO as stock prices may fluctuate in response to market news and sentiments. To further protect themselves against possible losses due to price fluctuations, investors should follow a well-diversified portfolio strategy rather than investing all their money into one particular company’s IPO.
Overall, checking your Mankind Pharma IPO allotment status is simple yet important step in ensuring a successful investment experience with this upcoming offering. By taking care to follow these steps and being aware of potential risks associated with IPOs, you can increase your chances of achieving desired returns on your investments over time.
0 Comments